### Guideline Page and Request

**FEV-9**  
External request: Submission from The Medicines Company to add oritavancin as a therapeutic option for the treatment of cellulitis/skin and soft tissue infections

Panel consensus to not include oritavancin for injection in the treatment pathway was based on the limited data. Studies have not included patients with cancer, and equivalence of long-acting agents for patients who are hospitalized has not been demonstrated. See submission letter for references.

<table>
<thead>
<tr>
<th>Institution Vote</th>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
<th>ABSENT</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
<td>14</td>
<td>0</td>
<td>11</td>
</tr>
</tbody>
</table>

### Guideline Page and Request

**FEV-B (page 1 of 5)**  
External request: Submission from Astellas Pharma Global Development, Inc., to add isavuconazonium sulfate as an appropriate systemic therapy for adult cancer patients and hematopoietic stem cell transplant (HSCT) recipients with invasive aspergillosis and invasive mucormycosis.

Based on the data in the noted references and discussion, the panel consensus was to add isavuconazonium sulfate as an approved drug for invasive refractory mold infections.

1. FDA Briefing Document. Anti-infective drugs advisory committee meeting.  

